Skip to main content
×

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

This website is intended for a global audience.

Home
  • About Us
    • History & Approach
    • Board of Directors
    • Executive Leadership
    • Our Values
    • News
  • Healthcare Professionals
    • Research & Trials
      • Therapeutic Areas
      • Cannabinoid Compounds
      • CBD Mechanism of Action
      • Research Papers
    • Pipeline
    • Epidiolex®
    • Sativex®
      • MS Spasticity
      • Information on Obtaining Sativex®
  • Patients & Caregivers
    • Sativex® Patient Information
  • Investors & Media
    • Financials
      • Financial Report
      • SEC Filings
      • Annual Meeting
      • Stock Information
      • Analyst Coverage
      • Securities In Issue
    • Shareholder Resources
      • Shareholder Services
      • AIM de-list
        • AIM de-list FAQ
        • Conversion of Ordinary shares into ADRs
        • Suggested Broker Contact for conversion of Ordinary Shares to ADRs
      • Shareholder FAQs
      • Annual Reports
    • Press Releases
    • Events/Media/ Contacts
      • Events & Presentations
      • Advisers
      • IR Contacts
    • Governance
      • Corporate Governance
      • Disclosure Policy
      • Code of Conduct Ethics
      • UK Tax Strategy
  • Careers
    • UK Careers
    • US Careers
  • Contact Us
    • Select a Region
    • European
    • Global Corporate
    • United States (US)
  1. Home
  2. Array

0000899243-21-002559

  • Read more about 0000899243-21-002559

Statement of changes in beneficial ownership of securities

0000899243-21-002560

  • Read more about 0000899243-21-002560

Statement of changes in beneficial ownership of securities

0000899243-21-002235

  • Read more about 0000899243-21-002235

Statement of changes in beneficial ownership of securities

0000899243-21-000785

  • Read more about 0000899243-21-000785

Statement of changes in beneficial ownership of securities

0000899243-21-000787

  • Read more about 0000899243-21-000787

Statement of changes in beneficial ownership of securities

0000899243-21-000786

  • Read more about 0000899243-21-000786

Statement of changes in beneficial ownership of securities

0000899243-21-000774

  • Read more about 0000899243-21-000774

Statement of changes in beneficial ownership of securities

0000899243-20-033832

  • Read more about 0000899243-20-033832

Statement of changes in beneficial ownership of securities

0000899243-20-033216

  • Read more about 0000899243-20-033216

Statement of changes in beneficial ownership of securities

0000899243-20-032605

  • Read more about 0000899243-20-032605

Statement of changes in beneficial ownership of securities

Pagination

  • Next page ››
Subscribe to 3,4,5

Footer

  • Home
  • About Us
  • Healthcare Professionals
  • Patients & Caregivers
  • Investors & Media
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use

GW Pharmaceuticals plc. All rights reserved

GWP-04748

This section of the website is reserved for healthcare professionals as it contains information about prescription medicines. Please confirm you are a healthcare professional to continue.

YES, I AM A HEALTHCARE PROFESSIONAL

NO, I AM NOT A HEALTHCARE PROFESSIONAL

Please note, you are now leaving www.gwpharm.com

OK

STAY ON SITE

COVID-19 UPDATE

We are closely monitoring our supply chain of EPIDIOLEX® (cannabidiol) and, at this time, do not foresee any supply interruptions in the United States.

At GW Pharmaceuticals, our main concern is the well-being of our patients, healthcare partners, and employees. Our hearts and thoughts go out to the people who have been affected. We are monitoring the COVID-19 situation and have taken steps to ensure that access and assistance for patients remain consistent.